DALLAS February 1, 2011
– Biopharmaceutical Market Worldwide is Set for High Growth.
The US biopharmaceutical market which has previously contributed 60% of world market share will witness a sudden growth spurt, triggered by a spate of policy changes, grants and the recent Health Care Reform Bill and AARC.
However, as the rest of the world (ROW) markets are also set for high growth and hence the overall contribution of US market share in the world market will decrease. FDA’s approval of more biopharma drugs into the market and the impact of expansion of therapeutic indications from existing products will also add to the biopharma market growth. The market will soon lose its clear-cut demarcation from the bionanotechnology product market with more companies looking to fuse and integrate biological components with this market segment. The analytical report, Strategic Analysis & Forecast of US Biopharmaceutical Industry (2009-2016): Impact of Healthcare Reform, Technological Innovation & Market, comprehensively investigates the global biopharmaceutical market – its growth factors, features, size, trends, services, tools, opportunities, restraints, drivers and product pipelines of some of the major pharmaceutical companies, while simultaneously drawing parallels with the US pharmaceutical market.
$106 billion $68 billion
The report primarily segregates the biopharmaceuticals market into the following segments in terms of the drug/product classifications. This also broadly determines the therapeutic application segments for this industry:
Antisense therapies Cytokines Proteins, enzymes and hormones Gene and cell therapies Monoclonal antibodies Vaccines Others: Including blood and allergenic components and some related bionanotechnology product such as Abraxane by Celgene acquired Abraxis Biosciences Inc., CA, USA.
In each of these market segments, a brief background is included. The report also includes total global market revenue forecasts, with US market size for the base year 2009.
Furthermore, this report forecasts revenue for all the individual product/drug class segments. The other segment includes biopharmaceuticals such as blood and allergenic factors and components.
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.)
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. M&M covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Contact: Mr. Rohan 7557 Rambler Road, Suite 727, Dallas, TX 75231 Tel: +1-888-600-6441 Email: [email protected] http://www.marketsandmarkets.com http://marketsandmarkets.blogspot.com
Dallas, TX [email protected]